Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Parkinsons Disease
- Therapeutic
- Alzheimer’s disease
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 117984
License Grant
Licensor grants to the German Licensee an exclusive worldwide license and / or sublicense, with a right to sublicense, under the Patents, the Know-How and the Joint Patents to use, develop, manufacture, have manufactured, market, sell, import for sale and distribute the Compound and / or the Product in the Territory for use in the Field. Licensor will grant additional sublicenses to third parties designated by Licensee.
License Property
Licensor is developing through its research and development activities a compound consisting of human retinal pigment epithelial cells on microcarriers for use, inter alia, in the treatment of Parkinsons Disease and Parkinsonian Movement Disorders.
Field of Use
Initial Indication is for the use of Product for the in vivo therapeutic prevention, treatment, cure or mitigation of Parkinsons Disease and / or Parkinsonian Movement Disorders.
IPSCIO Record ID: 213949
License Grant
Pursuant to the License Agreement, Licensor granted Licensee an exclusive, worldwide, royalty bearing license (with the right to grant sublicenses) in its intellectual property portfolio of materials and technology related to human stem cell derived photoreceptor cells and retinal pigment epithelial cells (the 'Licensed IP'), to use, commercialize and exploit any part thereof, in any manner whatsoever in the fields of the development and exploitation of (i) human stem cell derived photoreceptor cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders, and (ii) human stem cell derived retinal pigment epithelial cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders.
License Property
Intellectual property portfolio of materials and technology related to human stem cell derived photoreceptor cells and retinal pigment epithelial cells (the Licensed IP).
Field of Use
This agreement pertains to the medical industry relating to the fields of human stem cell therapy for the treatment of eye disorders.
IPSCIO Record ID: 362378
License Grant
Licensee was granted an exclusive license to use the MP Patents and know-how for the development, commercialization and exclusive license of MLR-1019.
License Property
MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Licensee’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. MLR-1019 (armesocarb) is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications.
Field of Use
Field of use is for the treatment of Parkinsons disease, a disorder of the central nervous system that affects movement, often including tremors.
IPSCIO Record ID: 362187
License Grant
Licensor hereby grants Licensee the exclusive right and license to practice the Licensor Patents and the Licensor Know-How to develop, have developed, make, have made, use, import, export, offer for sale, sell and have sold Licensed Products (including, but not limited to, Bulk Drug Substance) anywhere in the world. For so long as the license granted to Licensee under this agreement is in effect, Licensor forgoes the right to develop, have developed, make, have made, use, import, export, offer for sale, sell and have sold Licensed Products. The initial clinical studies for the Licensed Products shall be conducted under an EMEA CTA to be jointly filed by Licensor and Licensee.
If Licensee has completed the necessary steps to affect an Up-listing Event then Licensee will have the option at such time to purchase all rights, otherwise held by Licensor, for Licensed Products.
License Property
Compounds shall mean the compound known as MLR-1019, with the chemical name of R-mesocarb, including any salts and esters thereof.
MLR-1019 is a mirror image molecule called an enantiomer of mesocarb. Mesocarb is an approved medication that extends the amount of time that dopamine is available in the body by blocking cells’ ability to reabsorb it.
Melior Patents
Protocol Number MP2-201
Protocol Title A Multi-center, Double Blind, Randomized, Placebo-controlled, Flexible Dose-Escalagion, Phase IIa Study of MLR-1019 in Parkinson’s Patients With L-DOPA Induced Dyskinesias
Field of Use
Field shall mean all therapeutic applications and uses including Parkinson’s Patients. Designed to treat Parkinson’s motor and non-motor symptoms.
Parkinson's disease is a progressive nervous system disorder that affects movement. Symptoms start gradually, sometimes starting with a barely noticeable tremor in just one hand. Tremors are common, but the disorder also commonly causes stiffness or slowing of movement
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
